Fig. 1

HDAC inhibitors upregulate PLD2 expression in breast cancer cells. a The indicated cancer cells were treated with the HDAC inhibitors TSA (400 nM), SAHA (2 μM), and apicidin (5 μM) for 24 h. The lysates were then analyzed by q-PCR and western blot using the antibody to PLD2. b MDA-MB 231 cells were cultured and labeled with [³H] myristate for 12 h and treated with HDAC inhibitors for 1 h after which PLD activity was measured. c MDA-MB 231 cells were treated with the indicated concentrations of SAHA for 24 h or with 2 μM of SAHA for the indicated time, after which PLD2 expression and acetylated histone H4 levels were assessed by western blotting. d The cells were transfected with the pGL4-PLD2 promoter and treated with the indicated HDAC inhibitors for 24 h. The level of luciferase activity was then determined. The intensity of the indicated bands was normalized to the intensity of their respective α-tubulin bands and quantified against each other. Results are representative of at least four independent experiments and shown as the mean ± SEM. **p < 0.001 versus vehicle